Source comparison
BPC-157 and GHK-Cu Stack: Dosage and Timing Comparison
Research protocols using both peptides require structured dosing frameworks to maintain consistency across experimental groups and allow meaningful data interpretation. The table below outlines standard research dosing ranges, typical administration frequencie
This comparison does not assign a generated winner or score.
- Research protocols using both peptides require structured dosing frameworks to maintain consistency across experimental groups and allow meaningful data interpretation. The table below outlines standard research dosing ranges, typical administration frequencies, and the biological rationale for each compound when used in stacked protocols.
- BPC-157
- 250–500mcg per injection
- Once or twice daily
- VEGF upregulation, nitric oxide synthesis, growth factor receptor modulation
- 4–6 hours (rodent models)
- Systemic with preferential accumulation at injury sites
- Best for vascular and neural repair phases; administer early in repair timeline
- GHK-Cu
- 1–3mg per injection
- Once daily
- Copper delivery, collagen synthesis via lysyl oxidase, MMP regulation
- 24+ hours (when copper-bound)
- Dermal and connective tissue concentration
- Best for matrix remodeling phase; effects accumulate over 7–14 days
- Stacked Protocol
- BPC-157: 250mcg + GHK-Cu: 2mg
- BPC-157 twice daily, GHK-Cu once daily
- Complementary. Vascular (BPC) + structural (GHK) pathways addressed simultaneously
- Non-overlapping clearance profiles
- Separate injection sites recommended
- Allows concurrent targeting of angiogenesis and matrix synthesis without competitive inhibition
- Dosing precision matters because peptide activity isn't linear. Doubling the dose doesn't double the effect. BPC-157 demonstrates a dose-response curve in published tendon repair studies, with 10mcg/kg bodyweight (approximately 250–350mcg for a 70kg human-equivalent model) producing near-maximal VEGF expression. Doses above 500mcg per administration showed diminishing returns in rodent models, suggesting receptor saturation. GHK-Cu follows a similar pattern: doses below 1mg showed minimal collagen synthesis changes in dermal fibroblast cultures, while doses between 1–3mg produced the steepest increase in collagen type I deposition. Above 5mg, additional benefit plateaued, indicating the system's copper-handling capacity had been saturated.
- Timing also influences outcomes. BPC-157's short half-life (4–6 hours in circulation) means plasma levels drop significantly between once-daily administrations. Research teams investigating acute tissue repair often split the daily dose into twice-daily injections (morning and evening) to maintain more consistent receptor activation. GHK-Cu's longer stability when copper-bound allows once-daily dosing to sustain therapeutic tissue concentrations across 24-hour periods. In stacked protocols, this difference supports a dosing schedule of BPC-157 twice daily (separated by approximately 12 hours) and GHK-Cu once daily, typically administered alongside one of the BPC-157 doses for procedural convenience.